Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Norgine B.V.
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
- Drug Delivery
- Specialty Pharmaceuticals
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Azanta A/S
- Merus Labs Inc.
- Norgine Healthcare B.V
- Norgine Ventures Management Limited
- SpineVision SA
- SpePharm A.G.